Company Overview
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company based in the United States, primarily focused on the development of NDV-01, a controlled-release intravesical formulation combining gemcitabine and docetaxel for patients with aggressive forms of non-muscle invasive bladder cancer. The company functions within the Healthcare sector and the Biotechnology industry, where it pursues the advancement of novel therapies rather than commercializing established products. Its market capitalization stands at $698.57M, while its annual revenue is not disclosed in the provided financial data, and the employee count is listed as N/A. The substantial market cap of $698.57M relative to the lack of reported revenue suggests that the company's valuation is derived almost entirely from its clinical pipeline potential and future growth expectations rather than current operational earnings. This valuation structure indicates that the market places significant value on the company's intellectual property and the potential success of its Phase 2 clinical trials, positioning it as a speculative asset within the biotechnology landscape where success is binary and tied to clinical outcomes.
Financial Health
The company reports a net income of $-57,385,164 over the trailing twelve months, while revenue and EBITDA figures are not available in the provided data; the negative net income relative to the theoretical revenue gap reveals a cost structure characterized by high burn rates typical of clinical-stage development where expenses on research, trials, and personnel outweigh current sales. Free cash flow stands at $-26,079,348, indicating that the company is consuming cash reserves to fund its operations and development programs, which limits immediate financial flexibility but is a standard characteristic of early-stage biotech firms. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which reflects the absence of recognized revenue or a situation where costs have exceeded any generated income to the point of nullifying margins in the reporting period. The company holds $93.01M in cash against a debt level that is not applicable, resulting in a debt-to-equity ratio that is not applicable, which suggests a balance sheet funded almost exclusively by equity and cash reserves rather than leverage. The current ratio is a robust 14.62, indicating that the company possesses a very strong liquidity position with current assets significantly exceeding current liabilities, providing ample short-term resources to sustain operations. Return on Equity is -94.0% and Return on Assets is -52.8%, metrics that reveal management is currently deploying capital to generate losses rather than profits, which is expected for a company in the clinical development phase where the primary goal is asset building through trial completion rather than shareholder returns.
Valuation Assessment
The trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is -16.24, implying that the market is pricing in a future trajectory where the company is expected to remain unprofitable or has not yet established a path to positive earnings. The price-to-book ratio is 5.64, indicating that the market values the company at a significant premium over its book value, reflecting high expectations for the potential success of its clinical assets. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both not applicable, suggesting that traditional valuation multiples cannot be applied to a company with no revenue and negative earnings. The stock's 52-week high is $7.51 and the 52-week low is $0.24, meaning the current price sits within a range where the company has experienced extreme volatility, though the specific current price is not provided to calculate the exact percentage deviation. The beta value is 0.73, which indicates that the stock's price volatility is lower than the broader market, suggesting that despite its biotechnology nature, the share price has moved with less intensity than the overall market index during the observed period.
Growth & Income
Revenue growth and earnings growth rates are both not applicable in the provided data, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the lack of historical data precludes any analysis of growth trajectories. The company does not pay a dividend, as the dividend yield is not applicable and the payout ratio is 0.0%, meaning the company reinvests all available earnings and cash flow into its clinical development programs rather than distributing income to shareholders. Since the company does not pay dividends, the growth and income profile relies entirely on the potential appreciation of the stock price driven by the successful advancement of NDV-01 through clinical trials. The overall growth and income profile is characterized by a high-risk, high-reward dynamic typical of clinical-stage biotechnology, where income generation is absent in favor of capital expenditure on research and development.